• Earlier this month, Onto Innovation Inc. announced a collaboration with X-ray specialist Rigaku Holdings Corporation and a US$710,000,000 minority stake in Rigaku, alongside successful qualification of its Dragonfly G5 platform and raised revenue guidance for the first half of 2026.
• Together, these moves deepen Onto Innovation’s role in advanced process control and packaging, broadening its toolkit in X-ray metrology and AI-enabled inspection.
• We’ll now examine how the Rigaku collaboration and Dragonfly G5 momentum could influence Onto Innovation’s existing investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.

Onto Innovation Investment Narrative Recap

To own Onto Innovation, you generally need to believe that demand for advanced process control in AI-focused packaging and leading-edge nodes supports its premium valuation and ongoing R&D spend. Near term, execution on tools like Dragonfly and customer capex follow-through remain key catalysts, while heavy exposure to a handful of advanced customers and cyclical spending is still the central risk. The Rigaku stake and collaboration strengthen Onto’s technology story but do not remove that concentration risk.

Among the recent announcements, the Dragonfly G5 qualification for 2.5D advanced packaging stands out alongside the Rigaku news, because both speak directly to Onto’s process control positioning in AI-related packaging. Dragonfly G5’s new optics and AI-enhanced software, coupled with management’s expectation for more than 50% platform demand growth in 2026 versus 2025, help frame why investors are focused on whether Onto can convert today’s tool qualifications into sustained, higher quality revenue.

Yet while Onto is expanding its toolkit, investors should also be aware of how concentrated AI packaging and advanced logic exposure could quickly become a weakness if ...

Onto Innovation’s narrative projects $1.7 billion revenue and $428.9 million earnings by 2029.

Uncover how Onto Innovation's forecasts yield a $280.71 fair value, a 9% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected revenue near US$1.7 billion and earnings of about US$462 million by 2029, so this Rigaku collaboration and Dragonfly traction could either reinforce those bullish views or prompt a rethink of risks like heavier R&D demands, depending on how you weigh the same facts against very different future scenarios.

Explore 5 other fair value estimates on Onto Innovation - why the stock might be worth as much as $280.71!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Onto Innovation research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Onto Innovation research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Onto Innovation's overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Find 54 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.